Literature DB >> 24609760

Hypereosinophilia and seroconversion of rheumatoid arthritis.

Rachel K Rosenstein1, Richard S Panush, Neil Kramer, Elliot D Rosenstein.   

Abstract

At the intersection of atopy and autoimmunity, we present a patient with seronegative rheumatoid arthritis (RA) who developed hypereosinophilia, without evidence of other etiologies, as she became rheumatoid factor (RF) positive. Although the magnitude of eosinophilia in patients with RA has been thought to reflect the severity or activity of the RA, in our patient, eosinophilia developed at a time when the patient's synovitis was well controlled. Although eosinophilia may reflect associated drug hypersensitivity, discontinuation of the medications utilized to control our patient's disease, adalimumab and methotrexate, did not promote clinical improvement. Probably the most curious aspect of our patient was the concomitant development of rheumatoid factor seropositivity in the setting of previously seronegative RA. The temporal relationship between the development of peripheral eosinophilia and seroconversion suggests a possible connection between these events. We speculate that the T cell cytokine production that can induce eosinophilia may simultaneously activate RF production.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24609760     DOI: 10.1007/s10067-014-2566-6

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  27 in total

1.  Correlation between rheumatoid factor and peripheral eosinophil count in chronic eosinophilic pneumonia.

Authors:  Megumi Kudou; Hirotaka Yasuba; Yoshiki Kobayashi; Kazuyuki Hamada; Hideo Kita
Journal:  Respirology       Date:  2006-11       Impact factor: 6.424

2.  Rheumatoid arthritis, immune complex disease, and hypereosinophilic syndrome. Report on a case.

Authors:  G Hillerdal; B Marjanovic; H Aberg
Journal:  Acta Med Scand       Date:  1979

Review 3.  Eosinophils: biological properties and role in health and disease.

Authors:  Simon P Hogan; Helene F Rosenberg; Redwan Moqbel; Simon Phipps; Paul S Foster; Paige Lacy; A Barry Kay; Marc E Rothenberg
Journal:  Clin Exp Allergy       Date:  2008-04-01       Impact factor: 5.018

Review 4.  Immune-mediated adverse effects of biologicals used in the treatment of rheumatic diseases.

Authors:  Andrea T Borchers; Naama Leibushor; Gurtej S Cheema; Stanley M Naguwa; M Eric Gershwin
Journal:  J Autoimmun       Date:  2011-09-09       Impact factor: 7.094

Review 5.  Eosinophilic cellulitis (Wells' syndrome) as a cutaneous reaction to the administration of adalimumab.

Authors:  P Boura; A Sarantopoulos; I Lefaki; P Skendros; P Papadopoulos
Journal:  Ann Rheum Dis       Date:  2006-06       Impact factor: 19.103

6.  Human lymphocytes making rheumatoid factor and antibody to ssDNA belong to Leu-1+ B-cell subset.

Authors:  P Casali; S E Burastero; M Nakamura; G Inghirami; A L Notkins
Journal:  Science       Date:  1987-04-03       Impact factor: 47.728

7.  Response to corticosteroids in the hypereosinophilic syndrome. Association with increased serum IgE levels.

Authors:  R K Bush; M Geller; W W Busse; D K Flaherty; H A Dickie
Journal:  Arch Intern Med       Date:  1978-08

8.  Eosinophilic cellulitislike reaction to subcutaneous etanercept injection.

Authors:  Harry Winfield; Edward Lain; Thomas Horn; Jerri Hoskyn
Journal:  Arch Dermatol       Date:  2006-02

9.  Treatment of rheumatoid arthritis with imatinib mesylate: clinical improvement in three refractory cases.

Authors:  Kari K Eklund; Heikki Joensuu
Journal:  Ann Med       Date:  2003       Impact factor: 4.709

10.  Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis.

Authors:  Ricardo T Paniagua; Orr Sharpe; Peggy P Ho; Steven M Chan; Anna Chang; John P Higgins; Beren H Tomooka; Fiona M Thomas; Jason J Song; Stuart B Goodman; David M Lee; Mark C Genovese; Paul J Utz; Lawrence Steinman; William H Robinson
Journal:  J Clin Invest       Date:  2006-09-14       Impact factor: 14.808

View more
  4 in total

Review 1.  Eosinophilia.

Authors:  Anna Kovalszki; Peter F Weller
Journal:  Prim Care       Date:  2016-10-14       Impact factor: 2.907

2.  The Allelic Landscape of Human Blood Cell Trait Variation and Links to Common Complex Disease.

Authors:  William J Astle; Heather Elding; Tao Jiang; Dave Allen; Dace Ruklisa; Alice L Mann; Daniel Mead; Heleen Bouman; Fernando Riveros-Mckay; Myrto A Kostadima; John J Lambourne; Suthesh Sivapalaratnam; Kate Downes; Kousik Kundu; Lorenzo Bomba; Kim Berentsen; John R Bradley; Louise C Daugherty; Olivier Delaneau; Kathleen Freson; Stephen F Garner; Luigi Grassi; Jose Guerrero; Matthias Haimel; Eva M Janssen-Megens; Anita Kaan; Mihir Kamat; Bowon Kim; Amit Mandoli; Jonathan Marchini; Joost H A Martens; Stuart Meacham; Karyn Megy; Jared O'Connell; Romina Petersen; Nilofar Sharifi; Simon M Sheard; James R Staley; Salih Tuna; Martijn van der Ent; Klaudia Walter; Shuang-Yin Wang; Eleanor Wheeler; Steven P Wilder; Valentina Iotchkova; Carmel Moore; Jennifer Sambrook; Hendrik G Stunnenberg; Emanuele Di Angelantonio; Stephen Kaptoge; Taco W Kuijpers; Enrique Carrillo-de-Santa-Pau; David Juan; Daniel Rico; Alfonso Valencia; Lu Chen; Bing Ge; Louella Vasquez; Tony Kwan; Diego Garrido-Martín; Stephen Watt; Ying Yang; Roderic Guigo; Stephan Beck; Dirk S Paul; Tomi Pastinen; David Bujold; Guillaume Bourque; Mattia Frontini; John Danesh; David J Roberts; Willem H Ouwehand; Adam S Butterworth; Nicole Soranzo
Journal:  Cell       Date:  2016-11-17       Impact factor: 41.582

3.  Successful Switch to Golimumab for Eosinophilia and Skin Symptoms Related to Multiple Biologics in a Patient with Rheumatoid Arthritis.

Authors:  Naoto Azuma; Kiyoshi Matsui; Naoaki Hashimoto; Takahiro Yoshikawa; Hajime Sano
Journal:  Intern Med       Date:  2017-06-15       Impact factor: 1.271

Review 4.  Eosinophils in Autoimmune Diseases.

Authors:  Nicola L Diny; Noel R Rose; Daniela Čiháková
Journal:  Front Immunol       Date:  2017-04-27       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.